🟠 Moderate Evidence
Most people taking over-the-counter melatonin are consuming 20 to 30 times the physiological dose their body produces naturally, according to evidence summarized in recent meta-analyses. Your pineal gland releases roughly 0.3 mg of melatonin per night when it gets dark, yet store shelves are stocked with 5–10 mg pills—doses that exceed the amount needed to activate the brain’s master clock and shift your circadian rhythm.
Key takeaways
- The human body produces approximately 0.3 mg of melatonin nightly; common OTC formulations contain 5–10 mg, a 20–30× excess
- Melatonin’s circadian-shifting effect (chronobiotic effect) occurs at doses as low as 0.125 mg, with both MT1 and MT2 brain receptors saturating at very low concentrations
- Doses above the physiological range do not enhance sleep quality or maintenance but increase drowsiness, vivid dreams, and next-day grogginess
- Meta-analyses confirm melatonin modestly reduces sleep onset latency but does not improve total sleep quality in most populations
Study at a Glance
| Primary sources | Comai et al., Journal of Pineal Research, 2024; Ferracioli-Oda et al., PLoS One, 2013 |
| Evidence type | Meta-analysis and physiological research |
| Key finding | Receptor saturation occurs at doses 40–80× below typical OTC formulations |
| Clinical implication | Standard OTC doses exceed physiological requirement; modest sleep-onset benefit with no maintenance improvement |
Melatonin Dosing: Physiological vs. Typical OTC
Comparison of natural production, receptor saturation threshold, chronobiotic dose, and common retail formulations (mg)
Source: Comai et al., 2024; Ferracioli-Oda et al., 2013 | Georgian Medical Journal News
How melatonin works: two brain receptors, one saturation point
Melatonin exerts its sleep-promoting and circadian-regulating effects by binding to two specific receptors in the suprachiasmatic nucleus (SCN)—your brain’s master clock. According to Comai et al., published in the Journal of Pineal Research (2024), the MT1 receptor suppresses alerting signals and helps initiate sleep entry, while the MT2 receptor shifts your circadian phase timing—the molecular mechanism that determines whether you fall asleep earlier or later.
Both receptors saturate—reach full occupancy—at very low concentrations. This is the critical pharmacological detail absent from most consumer messaging. Saturation means additional melatonin cannot bind more receptors or activate them more strongly. Once the receptors are full, adding more drug does nothing to enhance the intended effect. It merely increases systemic exposure and the likelihood of adverse effects.
The dosing mismatch: why 10 mg is 33 times more than needed
Your body’s natural melatonin secretion peaks at roughly 0.3 mg per night, a physiologically precise amount refined by millions of years of evolution. The chronobiotic effect—the clock-shifting signal that tells your brain “it is now evening”—occurs at doses as low as 0.125 mg, according to the evidence reviewed by Ferracioli-Oda and colleagues in PLoS One (2013). This represents a 40-fold margin between the circadian threshold and your natural production.
Yet standard retail melatonin formulations contain 5–10 mg—a dose that exceeds natural production by 17 to 33 times. “Higher doses don’t produce a stronger timing signal,” the evidence indicates. Instead, they generate increased drowsiness, more vivid or disturbing dreams, and next-day grogginess—adverse effects that reflect excessive systemic melatonin rather than enhanced circadian precision. Patients often interpret these side effects as evidence the supplement is “working,” when in fact they are experiencing pharmacological overage.
Sleep onset vs. sleep maintenance: melatonin’s modest and narrow benefit
Meta-analyses synthesizing randomized controlled trials confirm that melatonin produces a modest reduction in sleep onset latency—the time it takes to fall asleep—across most populations, according to Ferracioli-Oda et al. However, the same body of evidence shows melatonin does not improve sleep maintenance (the ability to stay asleep) or total sleep quality in most people.
This distinction matters clinically. Standard immediate-release melatonin formulations have a half-life under one hour, meaning the drug is cleared from the bloodstream long before the second half of the night arrives—precisely when sleep maintenance becomes critical. Extended-release formulations have shown modest benefit for sleep maintenance in older adults, but this is a pharmacologically distinct product from the immediate-release supplements dominating pharmacy shelves and online retailers. Consumers purchasing a standard 10 mg immediate-release tablet at midnight will find little support for staying asleep 3–4 hours later.
When melatonin fails: reassessing the underlying problem
If a physiologically appropriate dose—0.3 to 0.5 mg taken 30 to 60 minutes before your target bedtime—does not improve sleep onset, the underlying cause likely is not melatonin deficiency. Insomnia and circadian misalignment arise from multiple sources: environmental light exposure, inconsistent sleep scheduling, caffeine timing, stress, comorbid psychiatric or medical conditions, and behavioral patterns. Escalating the melatonin dose does not address these root causes and merely accumulates side effects.
For patients with genuine circadian rhythm disorders—shift work sleep disorder, delayed sleep phase syndrome, or advanced sleep phase syndrome—melatonin’s chronobiotic effect at low doses may offer targeted benefit. For routine insomnia, evidence-based first-line interventions remain cognitive-behavioral therapy for insomnia (CBT-I), sleep hygiene optimization, and circadian-aligned light exposure. See Clinical Updates for guidance on non-pharmacological sleep interventions.
Both MT1 and MT2 melatonin receptors saturate at very low concentrations; the chronobiotic effect occurs at 0.125 mg, yet typical OTC formulations contain 5–10 mg, producing side effects without additional circadian benefit.
— Comai et al., Journal of Pineal Research (2024)
What this means
Frequently asked questions
Is melatonin safe at high doses?
Melatonin is generally well tolerated, but doses above physiological levels (>1 mg) increase adverse effects: next-day grogginess, vivid dreams, and occasionally daytime mood changes. Because melatonin is unregulated in most markets and formulations vary widely, long-term safety data at very high doses (10+ mg nightly) remain limited. For occasional use, high-dose melatonin carries low absolute risk, but efficacy does not improve above receptor saturation, making dose escalation irrational.
Why do OTC melatonin pills contain so much more than my body makes?
Regulatory oversight of supplements is minimal in most countries. Manufacturers began with arbitrary high doses based on early animal studies and cost considerations—melatonin is inexpensive to synthesize. Consumer perception conflated “more” with “better,” and marketing reinforced this misconception. Once market norms were established at 5–10 mg, changing formulations became difficult. Scientific evidence on optimal dosing was published decades after mass retail adoption, so correcting the market is slow.
Should I switch to a lower-dose melatonin product?
If melatonin is helping you fall asleep at your current dose, lowering it slightly (e.g., from 10 mg to 5 mg or 1 mg) may reduce next-day side effects without losing benefit, since receptor saturation occurs at much lower thresholds. However, if standard melatonin has not improved your sleep despite weeks of use, switching to an even lower dose is unlikely to help. At that point, consulting a sleep specialist for cognitive-behavioral therapy, circadian assessment, or evaluation for underlying sleep disorders is more evidence-based than further supplement adjustment.
The gap between melatonin’s physiological dose and typical OTC formulations reflects decades of regulatory ambiguity and marketing inertia rather than scientific optimization. Consumers and clinicians armed with receptor pharmacology can make more rational decisions: melatonin’s modest sleep-onset benefit occurs at doses 20–80 times lower than retail norms, and higher doses generate side effects, not efficacy. For genuine circadian disorders, low-dose melatonin with precise timing offers evidence-based value. For routine insomnia, behavioral interventions and sleep hygiene remain first-line, with melatonin a secondary option at physiologically appropriate doses.
Source: Comai et al., Journal of Pineal Research, 2024; Ferracioli-Oda et al., PLoS One, 2013
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
